312 related articles for article (PubMed ID: 31673229)
1. Current Advance in Thrombopoietin Receptor Agonists in the Management of Thrombocytopenia Associated With Chronic Liver Disease: Focus on Avatrombopag.
Abdela J
Clin Med Insights Blood Disord; 2019; 12():1179545X19875105. PubMed ID: 31673229
[TBL] [Abstract][Full Text] [Related]
2. Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis.
Armstrong N; Büyükkaramikli N; Penton H; Riemsma R; Wetzelaer P; Huertas Carrera V; Swift S; Drachen T; Raatz H; Ryder S; Shah D; Buksnys T; Worthy G; Duffy S; Al M; Kleijnen J
Health Technol Assess; 2020 Oct; 24(51):1-220. PubMed ID: 33108266
[TBL] [Abstract][Full Text] [Related]
3. Management of Thrombocytopenia in Patients with Chronic Liver Disease.
Saab S; Brown RS
Dig Dis Sci; 2019 Oct; 64(10):2757-2768. PubMed ID: 31011942
[TBL] [Abstract][Full Text] [Related]
4. Avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease.
Xu H; Cai R
Expert Rev Clin Pharmacol; 2019 Sep; 12(9):859-865. PubMed ID: 31352834
[No Abstract] [Full Text] [Related]
5. Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease.
Khemichian S; Terrault NA
Semin Thromb Hemost; 2020 Sep; 46(6):682-692. PubMed ID: 32820479
[TBL] [Abstract][Full Text] [Related]
6. Avatrombopag: A Review in Thrombocytopenia.
Markham A
Drugs; 2021 Nov; 81(16):1905-1913. PubMed ID: 34709601
[TBL] [Abstract][Full Text] [Related]
7. The Use of Thrombopoietin Receptor Agonists for Correction of Thrombocytopenia prior to Elective Procedures in Chronic Liver Diseases: Review of Current Evidence.
Qureshi K; Patel S; Meillier A
Int J Hepatol; 2016; 2016():1802932. PubMed ID: 27800187
[TBL] [Abstract][Full Text] [Related]
8. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.
Terrault N; Chen YC; Izumi N; Kayali Z; Mitrut P; Tak WY; Allen LF; Hassanein T
Gastroenterology; 2018 Sep; 155(3):705-718. PubMed ID: 29778606
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of avatrombopag for the treatment of thrombocytopenia.
Virk ZM; Kuter DJ; Al-Samkari H
Expert Opin Pharmacother; 2021 Feb; 22(3):273-280. PubMed ID: 33095074
[No Abstract] [Full Text] [Related]
10. Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease.
Michelson AD; Smolensky Koganov E; Forde EE; Carmichael SL; Frelinger AL
J Thromb Haemost; 2018 Dec; 16(12):2515-2519. PubMed ID: 30264918
[TBL] [Abstract][Full Text] [Related]
11. The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag.
Kuter DJ
Blood Rev; 2022 May; 53():100909. PubMed ID: 34815110
[TBL] [Abstract][Full Text] [Related]
12. Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies.
Poordad F; Terrault NA; Alkhouri N; Tian W; Allen LF; Rabinovitz M
Int J Hepatol; 2020; 2020():5421632. PubMed ID: 32047671
[TBL] [Abstract][Full Text] [Related]
13. Avatrombopag for the treatment of immune thrombocytopenia.
Długosz-Danecka M; Zdziarska J; Jurczak W
Expert Rev Clin Immunol; 2019 Apr; 15(4):327-339. PubMed ID: 30799645
[TBL] [Abstract][Full Text] [Related]
14. Real-world use of avatrombopag in patients with chronic liver disease and thrombocytopenia undergoing a procedure.
Satapathy SK; Sundaram V; Shiffman ML; Jamieson BD
Medicine (Baltimore); 2023 Oct; 102(40):e35208. PubMed ID: 37800793
[TBL] [Abstract][Full Text] [Related]
15. Review article: a treatment algorithm for patients with chronic liver disease and severe thrombocytopenia undergoing elective medical procedures in the United States.
Dieterich DT; Bernstein D; Flamm S; Pockros PJ; Reau N
Aliment Pharmacol Ther; 2020 Oct; 52(8):1311-1322. PubMed ID: 32813292
[TBL] [Abstract][Full Text] [Related]
16. Thrombocytopenia in Chronic Liver Disease and the Role of Thrombopoietin Agonists.
Miller JB; Figueroa EJ; Haug RM; Shah NL
Gastroenterol Hepatol (N Y); 2019 Jun; 15(6):326-332. PubMed ID: 31391802
[TBL] [Abstract][Full Text] [Related]
17. Treatment Options for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing a Scheduled Procedure.
Saab S; Bernstein D; Hassanein T; Kugelmas M; Kwo P
J Clin Gastroenterol; 2020 Jul; 54(6):503-511. PubMed ID: 32195771
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human thrombopoietin treatment in patients with chronic liver disease-related thrombocytopenia undergoing invasive procedures: A retrospective study.
Ding JN; Feng TT; Sun W; Cai XY; Zhang Y; Zhao WF
World J Gastrointest Surg; 2022 Nov; 14(11):1260-1271. PubMed ID: 36504518
[TBL] [Abstract][Full Text] [Related]
19. Lusutrombopag is effective and safe in patients with chronic liver disease and severe thrombocytopenia: a multicenter retrospective study.
Nomoto H; Morimoto N; Miura K; Watanabe S; Takaoka Y; Maeda H; Sasaki T; Koyashiki Y; Kurata H; Numao N; Isoda N; Yamamoto H
BMC Gastroenterol; 2020 Dec; 20(1):427. PubMed ID: 33317473
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and Safety of Avatrombopag in Liver Cancer Patients with Severe Thrombocytopenia: Real-World Data and Challenges.
Huang A; Chen JF; Wu JZ; Gao Z; Shi YH; Fu XT; Zhang X; Liu WR; Gao Q; Sun HC; Shi GM; Fan J; Ding ZB; Zhou J
J Oncol; 2022; 2022():9138195. PubMed ID: 36405248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
